Agenda: Day 1  | Day 2  |

 US Healthcare Reform-A New Dawn?

With the US market accounting for half of global drug sales, any changes as a result of current US healthcare reforms will have significant impacts for the global pharmaceutical industry. Extensions in insurance coverage to an additional 31m Americans can be expected to increase the overall size of the market, but could equally be counteracted by the prospect of increasing government intervention in pricing and reimbursement decisions. What does the detail of the reform plan tell us about what life science companies can expect from the US market in the years ahead? What will be the impact, if any, of the reforms on innovation in the US and internationally? 

As countries around the globe tackle the growing burden of costs and reform their healthcare systems, they are doing so around concepts of comparative effectiveness and value-based pricing-with major implications for life science companies and their global sales revenues.  A growing number of health technology assessment bureaus have been established in developed countries such as Canada, Germany, Sweden and Australia and the UK, and countries such as China are studying the advantages of such a system as part of their own healthcare reform programmes What are the different approaches being applied to evaluate and measure economic outcomes of different drugs in the different markets? To what degree are systems converging around a universal definition of value? Are existing and proposed models for determining cost and efficiency sufficiently robust? 

A Future Focussed on Value and Outcomes-Transforming the Business of Pharma 

The new international focus on value and outcomes as the basis of pricing and reimbursement decisions for pharmaceutical products and devices will have far reaching consequences for the industry. It will influence which drugs make their way through the labs. It will require a new type of sale force focussed on selling outcomes rather than products, and it will require an understanding that access and ownership of data will become the new competitive edge for the business. Faced with the realities of this new order, how can life science companies prepare? As consumers, likewise, become purveyors of value in the industry, how can life sciences companies build an understanding of, and influence their prescription choices? What are the new channels to reach and influence these choices e.g social media, and the challenges in doing so?

CFO Panel: Positioning for Growth

As CFOs move from keeping the score to "shaping the play", the initiatives they undertake, and the guidance they provide to strategy are having an increasingly important role in driving future revenue and the sustainable growth of the company. So what are the issues keeping the CFOs of today's life science companies awake at night, and what do they see as the trends shaping the business? From financing R&D, to maximising returns from M&A, and working out where the next generation of cost efficiencies will come from, what strategies are they employing to deal with the emerging industry challenges and position their companies for growth?